Reading NUVB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUVB free→Reading NUVB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUVB free→QuarterlyIQ Insights · NUVB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 4, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Ex…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 2, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under t…
Results of Operations and Financial Condition. On January 12, 2026, the Company issued a press release announcing, among other things, the Company’s preliminary unaudited cash, cash equivalents and marketable securities for the fiscal year ended December 31, 2025 and preliminary net product revenue of IBTROZI. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into a Material Definitive Agreement. On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”). Pursuant to the License Agreement, the Company granted Eisai an exclusive license to develop and commercialize licensed products containing taletrectinib in the following territories: the European Union and all member states thereof, Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On November 3, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing und…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 7, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…
Other Events. On June 11, 2025, Nuvation Bio Inc. (the “Company”) announced that the U.S. Food and Drug Administration has approved IBTROZI TM (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The FDA approval of IBTROZI is supported by one of the largest global clinical trial programs in ROS1+ NSCLC to date, with over 300 patients enrolled in the pivotal TRUST-I and TRUST-II studies. In TRUST-I, IBTROZI achieved…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 7, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Ex…
Entry into a Material Definitive Agreement. On March 21, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Life Science (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug product (the “Products”). Asymchem will be a non-exclusive supplier of the Products to the Company, and the Company will retain the right to procure the Products from one or more alternate and/or backup manufacturers of the Pr…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 6, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under t…
Entry into a Material Definitive Agreement. On March 3, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Laboratories (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug substance (the “Products”). Asymchem will be a non-exclusive supplier of the Products to the Company, and the Company will retain the right to procure the Products from one or more alternate and/or backup manufacturers of the P…
Entry into a Material Definitive Agreement. Loan Agreement On March 3, 2025 (the “Closing Date”), Nuvation Bio Inc. (the “Company”) entered into a $100.0 million senior secured loan agreement (the “Loan Agreement”), with Sagard Holdings Manager LP (“Sagard”) as administrative agent, and the lenders party thereto. An initial tranche of $50 million will be funded upon FDA Approval (as defined in the Loan Agreement) of taletrectinib on or prior to September 30, 2025. The second tranche of $50 mi…
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUVATION BIO INC. Date: March 4, 2025 By: /s/ Moses Makunje Name: Moses Makunje Title: Principal Accounting Officer
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals including China’s National Medical Products Administration’s approval of taletrectinib for the treatment of adult patients with advanced ROS1-posi…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.